The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Subscribe To Our Newsletter & Stay Updated
